Gera JF - Search Results

1

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression.

Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK. Gera JF, et al. J Biol Chem. 2004 Jan 23;279(4):2737-46. doi: 10.1074/jbc.M309999200. Epub 2003 Oct 23. J Biol Chem. 2004. PMID: 14576155 Free article.

2

Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: selective effects on HER2/neu-overexpressing cells.

Fady C, Gardner AM, Gera JF, Lichtenstein A. Fady C, et al. Among authors: gera jf. Cancer Res. 1992 Feb 15;52(4):764-9. Cancer Res. 1992. PMID: 1346583

3

Effects of beta-2 microglobulin anti-sense oligonucleotides on sensitivity of HER2/neu oncogene-expressing and nonexpressing target cells to lymphocyte-mediated lysis.

Lichtenstein A, Fady C, Gera JF, Gardner A, Chazin VR, Kelley D, Berenson J. Lichtenstein A, et al. Among authors: gera jf. Cell Immunol. 1992 Apr 15;141(1):219-32. doi: 10.1016/0008-8749(92)90141-b. Cell Immunol. 1992. PMID: 1348216

4

Inhibitors of ADP-ribose polymerase decrease the resistance of HER2/neu-expressing cancer cells to the cytotoxic effects of tumor necrosis factor.

Lichtenstein A, Gera JF, Andrews J, Berenson J, Ware CF. Lichtenstein A, et al. Among authors: gera jf. J Immunol. 1991 Mar 15;146(6):2052-8. J Immunol. 1991. PMID: 1672341

5

Human neutrophil peptide defensins induce single strand DNA breaks in target cells.

Gera JF, Lichtenstein A. Gera JF, et al. Cell Immunol. 1991 Nov;138(1):108-20. doi: 10.1016/0008-8749(91)90136-y. Cell Immunol. 1991. PMID: 1913832

6

Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes.

Lichtenstein A, Berenson J, Gera JF, Waldburger K, Martinez-Maza O, Berek JS. Lichtenstein A, et al. Among authors: gera jf. Cancer Res. 1990 Nov 15;50(22):7364-70. Cancer Res. 1990. PMID: 1977519

7

Resistance of HER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events.

Fady C, Gardner A, Gera JF, Lichtenstein A. Fady C, et al. Among authors: gera jf. Cancer Immunol Immunother. 1993 May;36(5):307-14. doi: 10.1007/BF01741169. Cancer Immunol Immunother. 1993. PMID: 8097427 Free PMC article.

8

Interferon-gamma-induced increased sensitivity of HER2/neu-overexpressing tumor cells to lymphokine-activated killer cell lysis: importance of ICAM-1 in binding and post-binding events.

Fady C, Gardner A, Gera JF, Lichtenstein A. Fady C, et al. Among authors: gera jf. Cancer Immunol Immunother. 1993 Oct;37(5):329-36. doi: 10.1007/BF01518456. Cancer Immunol Immunother. 1993. PMID: 8104695 Free PMC article.

9

Inhibition of DNA repair with aphidicolin enhances sensitivity of targets to tumor necrosis factor.

Gera JF, Fady C, Gardner A, Jacoby FJ, Briskin KB, Lichtenstein A. Gera JF, et al. J Immunol. 1993 Oct 1;151(7):3746-57. J Immunol. 1993. PMID: 8376804

10

Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.

Shi Y, Hsu JH, Hu L, Gera J, Lichtenstein A. Shi Y, et al. J Biol Chem. 2002 May 3;277(18):15712-20. doi: 10.1074/jbc.M200043200. Epub 2002 Feb 28. J Biol Chem. 2002. PMID: 11872747 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66 results

Search Page

Filters